Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells

por Cronauer, M V, Nessler-Menardi, C, Klocker, H, Maly, K, Hobisch, A, Bartsch, G, Culig, Z
Publicado 2000

Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

por Culig, Z, Hoffmann, J, Erdel, M, Eder, I E, Hobisch, A, Hittmair, A, Bartsch, G, Utermann, G, Schneider, M R, Parczyk, K, Klocker, H
Publicado 1999

Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells.

por Culig, Z., Hobisch, A., Herold, M., Hittmair, A., Thurnher, M., Eder, I. E., Cronauer, M. V., Rieser, C., Ramoner, R., Bartsch, G., Klocker, H., Konwalinka, G.
Publicado 1998

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling

por Nappo, G, Handle, F, Santer, F R, McNeill, R V, Seed, R I, Collins, A T, Morrone, G, Culig, Z, Maitland, N J, Erb, H H H
Publicado 2017

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer

por Puhr, M, Hoefer, J, Eigentler, A, Dietrich, D, van Leenders, G, Uhl, B, Hoogland, M, Handle, F, Schlick, B, Neuwirt, H, Sailer, V, Kristiansen, G, Klocker, H, Culig, Z
Publicado 2016